Applied Behavior Analysis Market Research in Orlando and Winter Garden, Florida: Industry Players Indicate Greatest Challenges they Face in 2022 Workforce
November 11, 2022 08:18 ET
|
Research and Markets
Dublin, Nov. 11, 2022 (GLOBE NEWSWIRE) -- The "Applied Behavior Analysis Market Research in Orlando and Winter Garden, Florida" report has been added to ResearchAndMarkets.com's offering. The...
PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA
November 02, 2022 09:00 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) is pleased to announce that it has submitted its pre-IND data meeting package to the US Food and Drug...
Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022
November 01, 2022 08:00 ET
|
Axial Therapeutics
WOBURN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...
CentralReach Announces Honorees for First-Ever Autism and IDD Care Awards
October 28, 2022 11:33 ET
|
CentralReach
Fort Lauderdale, FL, Oct. 28, 2022 (GLOBE NEWSWIRE) -- CentralReach, the leading provider of Autism and IDD Care software, announced the winners of the company’s first-ever Autism and IDD Care...
Book Featuring Autistic Superhero Released
October 19, 2022 12:01 ET
|
T. Alan Horne, author
SALT LAKE CITY, Oct. 19, 2022 (GLOBE NEWSWIRE) -- A new young adult novel featuring a neurodiverse superhero was released today—Advent 9, by author T. Alan Horne. Horne, who like his protagonist...
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
October 13, 2022 08:00 ET
|
Sema4
Research from 19,000 patients with Autism Spectrum Disorders found approximately 90% had prior negative tests, likely contributing to a longer time to diagnosis Data will be presented at the Child...
Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments
October 11, 2022 08:00 ET
|
Axial Therapeutics
- Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 - - Team also supporting additional microbiome-based small molecule...
GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders
October 07, 2022 09:20 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid...
Axial Therapeutics to Present at BioJapan Conference
October 06, 2022 08:00 ET
|
Axial Therapeutics
WOBURN, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...
Little Leaves Behavioral Services Opens New Location in Lutherville, Maryland
September 29, 2022 08:51 ET
|
Little Leaves
LUTHERVILLE, Md., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Little Leaves Behavioral Services, a leading provider of center-based behavioral health services for preschool-aged children on the autism...